A controlled trial of antihuman lymphocyte globulin (Behring) in cadaveric renal transplantation: improvement in graft and patient survival at one year using a high-dose regimen.
A controlled study of the effect of antihuman lymphocyte globulin (AHLG) on patient and kidney transplant survival has been performed. The AHLG was administered as an adjuvant to the routine immunosuppressive drugs in either high (30 mg/kg) or low (15 mg/kg) doses, control patients received no AHLG. The clinical condition of the recipients and the quality and the degree of immunological compatibility of the transplants were comparable. During the period of the study, the results of all first-time cadaver-kidney transplantations to non-diabetic uraemic patients were included. The actuarial graft survival rates at 12 months for the three groups (high dose, low dose and control) were 67%, 49% and 35%. The corresponding patient survival rates were 91%, 66% and 65% respectively. The difference between the results in the high dose AHLG and in the control group was significant (p less than 0.05).
D000961:Antilymphocyte Serum / Q000008:administration & dosage* / Q000627:therapeutic use; D001379:Azathioprine / Q000008:administration & dosage; D002102:Cadaver; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005916:Globulins / Q000008:administration & dosage; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007676:Kidney Failure, Chronic / Q000401:mortality; D016030:Kidney Transplantation; D011241:Prednisone / Q000008:administration & dosage; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum; D005916:Globulins; D007166:Immunosuppressive Agents; D001379:Azathioprine; D011241:Prednisone